Discovery of novel Bruton’s tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold

This publication has 10 references indexed in Scilit:

• Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases
  Bioorganic & Medicinal Chemistry Letters, 2014
• RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents
  The Journal of Pharmacology and Experimental Therapeutics, 2012
• Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies
  Journal of Medicinal Chemistry, 2012
• Antiarthritis Effect of a Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy
  The Journal of Pharmacology and Experimental Therapeutics, 2011
• Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
  Nature Chemical Biology, 2010
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
  Proceedings of the National Academy of Sciences, 2010
• Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
  Immunological Reviews, 2009
• Activation Mechanism and Steady State Kinetics of Bruton's Tyrosine Kinase
  Journal of Biological Chemistry, 2007
• Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
  Cell, 1993
• The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases
  Nature, 1993